Document is current
Any future updates will be listed below
-
Authors
Kim, Daniel S.
Risca, Viviana I.
Reynolds, David L.
Chappell, James
Rubin, Adam J.
Jung, Namyoung
Donohue, Laura K. H. https://orcid.org/0000-0002-1346-2840
Lopez-Pajares, Vanessa
Kathiria, Arwa
Shi, Minyi
Zhao, Zhixin
Deep, Harsh
Sharmin, Mahfuza
Rao, Deepti
Lin, Shin
Chang, Howard Y. https://orcid.org/0000-0002-9459-4393
Snyder, Michael P. https://orcid.org/0000-0003-0784-7987
Greenleaf, William J. https://orcid.org/0000-0003-1409-3095
Kundaje, Anshul
Khavari, Paul A. https://orcid.org/0000-0003-0098-4989
- License Information
-
More Information
Article History
Received: 9 November 2020
Accepted: 1 September 2021
First Online: 14 October 2021
Competing interests
: H.Y.C. is a cofounder of Accent Therapeutics and Boundless Bio and is an advisor to 10x Genomics, Arsenal Biosciences and Spring Discovery. M.P.S. is a cofounder and on the advisory board of Personalis, SensOmics, January, Filtricine, Qbio, Protos, Mirive and Nimo. M.P.S. is also on the advisory board of Genapsys and Tailai. W.J.G. is a consultant for 10x Genomics who has licensed intellectual property associated with ATAC-seq. W.J.G. has additional affiliations with Guardant Health (consultant) and Protillion Biosciences (cofounder and consultant). A. Kundaje has affiliations with Biogen (consultant), ImmuneAI (scientific advisory board) and RavelBio (scientific cofounder and scientific advisory board). The remaining authors declare no competing interests.
